Ozempic vs Wegovy 2026: Cost, Dose & Coverage
Ozempic and Wegovy are both semaglutide medications made by the same manufacturer, but Ozempic is FDA-approved for type 2 diabetes while Wegovy is FDA-approved for chronic weight management in non-diabetic patients. Wegovy uses higher doses (2.4 mg maximum) compared to Ozempic's typical diabetes dosing (1-2 mg), and Wegovy is marketed and priced differently despite containing the same active ingredient.
Ozempic
GLP-1 receptor agonist approved by FDA for type 2 diabetes blood sugar control
Type 2 diabetic patients seeking improved glucose control with secondary weight loss benefits, and those prioritizing insurance coverage
Wegovy
GLP-1 receptor agonist approved by FDA specifically for chronic weight management
Non-diabetic patients prioritizing weight loss, those willing to pay out-of-pocket, and patients seeking maximum approved semaglutide dosing
Quick Answer
AI SummaryOzempic and Wegovy are both semaglutide medications made by the same manufacturer, but Ozempic is FDA-approved for type 2 diabetes while Wegovy is FDA-approved for chronic weight management in non-diabetic patients. Wegovy uses higher doses (2.4 mg maximum) compared to Ozempic's typical diabetes dosing (1-2 mg), and Wegovy is marketed and priced differently despite containing the same active ingredient.
Our Verdict
AI-assistedChoose Ozempic if you have type 2 diabetes and need better insurance coverage—it's the same medication at lower approved doses with higher likelihood of insurance reimbursement. Choose Wegovy if your primary goal is weight loss without diabetes, you're uninsured or willing to pay out-of-pocket, and you want the higher 2.4 mg dose shown to produce greater weight loss (~15% vs 5-7%). Both medications carry identical side effect profiles; the choice primarily hinges on medical indication, dosing needs, and insurance coverage status.
Was this verdict helpful?
Choose Ozempic if
Best pickType 2 diabetic patients seeking improved glucose control with secondary weight loss benefits, and those prioritizing insurance coverage
Choose Wegovy if
Non-diabetic patients prioritizing weight loss, those willing to pay out-of-pocket, and patients seeking maximum approved semaglutide dosing
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- FDA-Approved Indication:Type 2 diabetes management vs Chronic weight management (non-diabetic)
- Maximum Approved Dose:✓ Wegovy wins(2.4 mg weekly vs 2 mg weekly)
- Average Monthly Cost (Uninsured):✓ Ozempic wins($900-1,200 vs $1,300-1,500)
Key Facts & Figures
30 numeric metrics compared
| Metric | Ozempic | Wegovy | Ratio |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300 | |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation) | |
| FDA Approval Year | 2017 | 2021 | |
| Number of Dose Strengths Available(strengths) | 4 | 5 | |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22% | |
| FDA Approval Year(year) | 2017 (diabetes) | 2021 (weight management) | |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% | |
| Injection Frequency(times per week) | 1 | 1 | |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | $1,350-1,600 | |
| Time to Maintenance Dose(weeks) | 12 | 16 | |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | 0.5-1.0 | |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — | — |
| Injection Schedule(per week) | Once weekly | — | — |
| Average Retail Price(USD/month) | $900-1,300 | — | — |
| Number of Dose Strengths Available(options) | 3 | — | — |
| Time on Market(years) | 9 years | — | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | 2.4mg weekly | |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction | |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | $1,349-$1,550 | |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | 25% (at 2.4mg dose) | |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | 35-45% (weight loss coverage limited) | |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg | |
| Average Weight Loss (Clinical Trial)(% body weight) | 5-7% (diabetes indication) | 15% (weight management trials) | |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks | |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | $1,300-1,500 | |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | 10-20% (excluded as cosmetic) | |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — | — |
Sourced from publicly available data ·
Key Differences
7 attributes compared head-to-head
- Type 2 diabetes managementFDA-Approved IndicationChronic weight management (non-diabetic)
- 2 mg weeklyMaximum Approved Dose2.4 mg weekly(winner)
- $900-1,200(winner)Average Monthly Cost (Uninsured)$1,300-1,500
- High (diabetes is covered indication)(winner)Insurance Coverage LikelihoodLower (weight loss often excluded)
- 5-7% body weight (typical diabetes use)Average Weight Loss at Max Dose15% body weight (clinical trial average)(winner)
- 8-12 weeksOnset of Weight Loss4-8 weeks(winner)
- SemaglutideActive Pharmaceutical IngredientSemaglutide (identical)
- FDA-Approved Indication
Ozempic
Type 2 diabetes management
Wegovy
Chronic weight management (non-diabetic)
- Maximum Approved Dose
Ozempic
2 mg weekly
Wegovy
2.4 mg weekly(winner)
- Average Monthly Cost (Uninsured)
Ozempic
$900-1,200(winner)
Wegovy
$1,300-1,500
- Insurance Coverage Likelihood
Ozempic
High (diabetes is covered indication)(winner)
Wegovy
Lower (weight loss often excluded)
- Average Weight Loss at Max Dose
Ozempic
5-7% body weight (typical diabetes use)
Wegovy
15% body weight (clinical trial average)(winner)
- Onset of Weight Loss
Ozempic
8-12 weeks
Wegovy
4-8 weeks(winner)
- Active Pharmaceutical Ingredient
Ozempic
Semaglutide
Wegovy
Semaglutide (identical)
Full Comparison
| Attribute | Ozempic | Wegovy |
|---|---|---|
| Average Weight Loss(%) | 8-12% | 15-22%(winner) |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22%(winner) |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction(winner) |
Show 1 more attributeAverage Weight Loss (Clinical Trial)(% body weight) 5-7% (diabetes indication) 15% (weight management trials) | ||
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300(winner) |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200(winner) | $1,350-1,600 |
| Average Retail Price(USD/month) | $900-1,300 | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100(winner) | $1,349-$1,550 |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200(winner) | $1,300-1,500 |
| Active Ingredient | Semaglutide | Semaglutide |
| Active Pharmaceutical Ingredient | Semaglutide (recombinant human GLP-1 analog) | Semaglutide (recombinant human GLP-1 analog) |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation)(winner) |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly(winner) | 2.4mg weekly |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg(winner) |
| FDA Approval Year | 2017(winner) | 2021 |
| FDA Approval Year(year) | 2017 (diabetes)(winner) | 2021 (weight management) |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — |
| Primary Indication | Type 2 Diabetes | Weight Loss & Obesity |
| Cardiovascular Benefits | Proven in diabetic patients | Proven in overweight/obese patients |
| Typical Insurance Coverage | Widely covered for diabetes | Limited coverage for weight loss |
| Number of Dose Strengths Available(strengths) | 4 | 5(winner) |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | Semaglutide (GLP-1 receptor agonist) |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose)(winner) | 25% (at 2.4mg dose) |
| Injection Frequency(times per week) | 1 | 1 |
| Injection Schedule(per week) | Once weekly | — |
| Time to Maintenance Dose(weeks) | 12(winner) | 16 |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0(winner) | 0.5-1.0 |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | — |
| Number of Dose Strengths Available(options) | 3 | — |
| Time on Market(years) | 9 years | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication)(winner) | 35-45% (weight loss coverage limited) |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks(winner) |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label)(winner) | 10-20% (excluded as cosmetic) |
| Injection Frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — |
OzempicWegovyShow 1 more attribute
Pros & Cons
10 pros·4 cons across both
Ozempic
Pros
- FDA-approved specifically for type 2 diabetes, increasing insurance coverage likelihood
- Lower out-of-pocket costs ($900-1,200/month uninsured) compared to Wegovy
- Effective for both glucose control and modest weight loss (5-7% body weight)
- Established prescribing patterns mean more physician familiarity with diabetes dosing
- May be covered by Medicare Part D for eligible patients with diabetes
Cons
- Maximum approved dose of 2 mg is lower than Wegovy's 2.4 mg, limiting weight loss potential for non-diabetic patients
- Off-label use for weight loss in non-diabetics may not be covered by insurance
Wegovy
Pros
- Higher maximum dose of 2.4 mg produces significantly greater weight loss (~15% body weight average in trials)
- FDA-approved indication for chronic weight management appeals to non-diabetic patients seeking pure weight loss
- Faster onset of weight loss effects (4-8 weeks vs 8-12 weeks for Ozempic)
- Direct marketing and physician awareness for weight management indication
- Same pharmaceutical formulation as Ozempic with identical safety profile
Cons
- Higher out-of-pocket cost ($1,300-1,500/month uninsured) due to weight loss indication and higher approved dosing
- Insurance coverage significantly lower—most plans exclude weight loss as non-essential, leaving patients uninsured
Frequently Asked Questions
5 questions
Yes, many physicians prescribe Ozempic off-label for weight loss in non-diabetic patients, and some insurance plans will cover it in this context (50-65% likelihood). However, this is technically an off-label use, and insurance coverage is less certain than for its FDA-approved diabetes indication. Wegovy is the FDA-approved option specifically for non-diabetic weight management, though it carries higher out-of-pocket costs and lower insurance coverage rates (10-20%).
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
Related Comparisons
12 more to explore
Ozempic vs Wegovy
healthOzempic vs Mounjaro
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
healthContact Lenses vs Glasses
health
Related Articles
1 article
Explore More
Related comparisons and categories